Old Web
English
Sign In
Acemap
>
authorDetail
>
Hideka Inoue
Hideka Inoue
Randomized controlled trial
Ipragliflozin
Diabetes mellitus
Endocrinology
Internal medicine
3
Papers
19
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Ipragliflozin, an SGLT2 Inhibitor, Reduces Body Weight and Fat Mass, but not Muscle Mass, in Japanese Type 2 Diabetic Patients Treated with Insulin: A Randomized Clinical Trial
2019
Journal of Diabetes Investigation
Hideka Inoue
Katsutaro Morino
Satoshi Ugi
Sachiko Tanaka-Mizuno
Keiko Fuse
Itsuko Miyazawa
Keiko Kondo
Daisuke Sato
Natsuko Ohashi
Shogo Ida
Osamu Sekine
Masahiro Yoshimura
Kiyoshi Murata
Katsuyuki Miura
Hisatomi Arima
Hiroshi Maegawa
Show All
Source
Cite
Save
Citations (0)
Ipragliflozin, a SGLT2 Inhibitor, Reduced Body Weight and Fat Mass but Not Muscle Mass in Japanese Type 2 Diabetic Patients Treated with Insulin—A Randomized Clinical Trial
2018
Diabetes
Katsutaro Morino
Hideka Inoue
Keiko Fuse
Sachiko Tanaka
Keiko Kondo
Hisatomi Arima
Katsuyuki Miura
Daisuke Sato
Natsuko Ohashi
Shogo Ida
Itsuko Miyazawa
Osamu Sekine
Satoshi Ugi
Hiroshi Maegawa
Show All
Source
Cite
Save
Citations (0)
Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial
2018
Journal of Diabetes Investigation
Hideka Inoue
Katsutaro Morino
Satoshi Ugi
Sachiko Tanaka-Mizuno
Keiko Fuse
Itsuko Miyazawa
Keiko Kondo
Daisuke Sato
Natsuko Ohashi
Shogo Ida
Osamu Sekine
Masahiro Yoshimura
Kiyoshi Murata
Katsuyuki Miura
Hisatomi Arima
Hiroshi Maegawa
Show All
Source
Cite
Save
Citations (19)
1